Plazomicin Against Multidrug-Resistant Bacteria: A Scoping Review

Overview

Journal Life (Basel)

Specialty Biology

Date 2022 Dec 23

PMID 36556314

Authors

Aniello Alfieri

Sveva Di Franco

Valerio Donatiello

Vincenzo Maffei

Ciro Fittipaldi

Marco Fiore

Francesco Coppolino

Pasquale Sansone

Maria Caterina Pace

Maria Beatrice Passavanti

Affiliations

Soon will be listed here.

Abstract

Plazomicin is a next-generation semisynthetic aminoglycoside antibiotic that can be used to treat infections by multi-resistant bacteria. It is effective against many bacteria-producing carbapenemases or other specific hydrolases. This scoping review aims to define the role acquired by plazomicin from its approval by the FDA (US Food and Drug Administration) in 2018 to the present day. Furthermore, we aim to provide a base for a future meta-analysis. This project was conducted following the recommendations presented in the PRISMA extension for scoping reviews and the JBI Manual for Evidence Synthesis. Among 901 potentially engaging citations, 345 duplicates were removed, and only 81 articles were selected for the analysis. According to the data analysis, plazomicin has been used to treat urinary tract infections, bloodstream infections, and ventilation-associated pneumonia. The pathogens killed included multi-resistant , , , , and . Plazomicin can be a manageable, valid non-beta-lactam alternative for treating multi-resistant bacteria infections.

Citing Articles

Nebulized aminoglycosides for ventilator-associated pneumonia: Methodological considerations and lessons from experimental studies.

Rouby J, Xia J, Dhanani J, Li Bassi G, Monsel A, Torres A J Intensive Med. 2025; 5(1):12-22.

PMID: 39872832 PMC: 11764037. DOI: 10.1016/j.jointm.2024.07.006.

War and peace: exploring microbial defence systems as a source of new antimicrobial therapies.

Dyson P, Banat I, Quinn G Front Pharmacol. 2025; 15():1504901.

PMID: 39840088 PMC: 11747395. DOI: 10.3389/fphar.2024.1504901.

Environmental Antimicrobial Resistance: Implications for Food Safety and Public Health.

Ifedinezi O, Nnaji N, Anumudu C, Ekwueme C, Uhegwu C, Ihenetu F Antibiotics (Basel). 2024; 13(11).

PMID: 39596781 PMC: 11591122. DOI: 10.3390/antibiotics13111087.

A dual-function chromogenic and fluorogenic benzofurazan probe for plazomicin and its innovative utility for development of two microwell assays with high throughput for analysis of drug substance and pharmaceutical formulations.

Alkathiri F, Al-Outaibi M, Darwish I RSC Adv. 2024; 14(37):27215-27226.

PMID: 39193289 PMC: 11348761. DOI: 10.1039/d4ra04882b.

Structure-Activity Relationship of Pyrrolidine Pentamine Derivatives as Inhibitors of the Aminoglycoside 6'--Acetyltransferase Type Ib.

Sklenicka J, Tran T, Ramirez M, Donow H, Magana A, LaVoi T Antibiotics (Basel). 2024; 13(7).

PMID: 39061354 PMC: 11274322. DOI: 10.3390/antibiotics13070672.

References

Armstrong E, Miller G . Combating evolution with intelligent design: the neoglycoside ACHN-490. Curr Opin Microbiol. 2010; 13(5):565-73. DOI: 10.1016/j.mib.2010.09.004. View

Wright H, Bonomo R, Paterson D . New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?. Clin Microbiol Infect. 2017; 23(10):704-712. DOI: 10.1016/j.cmi.2017.09.001. View

Thwaites M, Hall D, Stoneburner A, Shinabarger D, Serio A, Krause K . Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae. Diagn Microbiol Infect Dis. 2018; 92(4):338-345. DOI: 10.1016/j.diagmicrobio.2018.07.006. View

Clark J, Burgess D . Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance. Ther Adv Infect Dis. 2020; 7:2049936120952604. PMC: 7475792. DOI: 10.1177/2049936120952604. View

McKinnell J, Dwyer J, Talbot G, Connolly L, Friedland I, Smith A . Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae. N Engl J Med. 2019; 380(8):791-793. DOI: 10.1056/NEJMc1807634. View

Coppola N, Maraolo A, Onorato L, Scotto R, Calo F, Atripaldi L . Epidemiology, Mechanisms of Resistance and Treatment Algorithm for Infections Due to Carbapenem-Resistant Gram-Negative Bacteria: An Expert Panel Opinion. Antibiotics (Basel). 2022; 11(9). PMC: 9495208. DOI: 10.3390/antibiotics11091263. View

Gall J, Choi T, Riddle V, Van Wart S, Gibbons J, Seroogy J . A Phase 1 Study of Intravenous Plazomicin in Healthy Adults to Assess Potential Effects on the QT/QTc Interval, Safety, and Pharmacokinetics. Clin Pharmacol Drug Dev. 2019; 8(8):1032-1041. DOI: 10.1002/cpdd.653. View

Di Franco S, Alfieri A, Fiore M, Fittipaldi C, Pota V, Coppolino F . A Literature Overview of Secondary Peritonitis Due to Carbapenem-Resistant Enterobacterales (CRE) in Intensive Care Unit (ICU) Patients. Antibiotics (Basel). 2022; 11(10). PMC: 9598607. DOI: 10.3390/antibiotics11101347. View

Hawkey P, Warren R, Livermore D, McNulty C, Enoch D, Otter J . Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party. J Antimicrob Chemother. 2018; 73(suppl_3):iii2-iii78. DOI: 10.1093/jac/dky027. View

10.

Hansen G . Continuous Evolution: Perspective on the Epidemiology of Carbapenemase Resistance Among Enterobacterales and Other Gram-Negative Bacteria. Infect Dis Ther. 2021; 10(1):75-92. PMC: 7954928. DOI: 10.1007/s40121-020-00395-2. View

11.

Adrie C, Garrouste-Orgeas M, Essaied W, Schwebel C, Darmon M, Mourvillier B . Attributable mortality of ICU-acquired bloodstream infections: Impact of the source, causative micro-organism, resistance profile and antimicrobial therapy. J Infect. 2016; 74(2):131-141. DOI: 10.1016/j.jinf.2016.11.001. View

12.

Fosso M, Li Y, Garneau-Tsodikova S . New trends in aminoglycosides use. Medchemcomm. 2014; 5(8):1075-1091. PMC: 4111210. DOI: 10.1039/C4MD00163J. View

13.

Jospe-Kaufman M, Siomin L, Fridman M . The relationship between the structure and toxicity of aminoglycoside antibiotics. Bioorg Med Chem Lett. 2020; 30(13):127218. PMC: 7194799. DOI: 10.1016/j.bmcl.2020.127218. View

14.

Eljaaly K, Alharbi A, Alshehri S, Ortwine J, Pogue J . Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections. Drugs. 2019; 79(3):243-269. DOI: 10.1007/s40265-019-1054-3. View

15.

Kotra L, Haddad J, Mobashery S . Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob Agents Chemother. 2000; 44(12):3249-56. PMC: 90188. DOI: 10.1128/AAC.44.12.3249-3256.2000. View

16.

Saravolatz L, Stein G . Plazomicin: A New Aminoglycoside. Clin Infect Dis. 2019; 70(4):704-709. DOI: 10.1093/cid/ciz640. View

17.

Earle W, Bonegio R, Smith D, Branch-Elliman W . Plazomicin for the treatment of multidrug-resistant bacteraemia in a patient with underlying chronic kidney disease and acute renal failure requiring renal replacement therapy. BMJ Case Rep. 2021; 14(8). PMC: 8378394. DOI: 10.1136/bcr-2021-243609. View

18.

Choi T, Komirenko A, Riddle V, Kim A, Dhuria S . No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects. Clin Pharmacol Drug Dev. 2019; 8(6):818-826. DOI: 10.1002/cpdd.648. View

19.

Wagenlehner F, Cloutier D, Komirenko A, Cebrik D, Krause K, Keepers T . Once-Daily Plazomicin for Complicated Urinary Tract Infections. N Engl J Med. 2019; 380(8):729-740. DOI: 10.1056/NEJMoa1801467. View

20.

Doi Y, Wachino J, Arakawa Y . Aminoglycoside Resistance: The Emergence of Acquired 16S Ribosomal RNA Methyltransferases. Infect Dis Clin North Am. 2016; 30(2):523-537. PMC: 4878400. DOI: 10.1016/j.idc.2016.02.011. View